Molecular Targeting in Cancer: Imaging and Therapy

A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Pathophysiology".

Deadline for manuscript submissions: closed (15 September 2022) | Viewed by 8575

Special Issue Editor

Division of Oncology, Department of Medicine, University of Washington, Seattle, WA 98109, USA
Interests: cancer therapeutic approaches; hematology oncology; targeted therapies

Special Issue Information

Dear Colleagues,

The objective of this Special Issue on “Molecular Targeting in Cancer: Imaging and Therapy” is to publish original research articles and reviews on molecular targeted approaches aimed at visualizing and treating tumors, particularly metastatic disease. Topics suitable for this issue include, but are not limited to, the following:

(1) molecular probes for image-guided surgery and image-guided drug delivery;

(2) targeted combination therapies;

(3) quantification of receptor binding potential;

(4) multi-modality molecular imaging;

(5) molecular targeting and physical stress in the tumor microenvironment;

(6) targeted therapies to overcome drug resistance.

Dr. Seth M Pollack
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • targeted combination therapy
  • molecular imaging
  • image-guided drug delivery
  • image-guided surgery
  • physical stress
  • drug resistance

Published Papers (3 papers)

Order results
Result details
Select all
Export citation of selected articles as:

Research

Jump to: Review

11 pages, 2510 KiB  
Article
HER2-Targeted Antibody–Drug Conjugates Display Potent Antitumor Activities in Preclinical Extramammary Paget’s Disease Models: In Vivo and Immunohistochemical Analyses
by Keiko Tokuchi, Takuya Maeda, Shinya Kitamura, Teruki Yanagi and Hideyuki Ujiie
Cancers 2022, 14(14), 3519; https://0-doi-org.brum.beds.ac.uk/10.3390/cancers14143519 - 20 Jul 2022
Cited by 3 | Viewed by 2103
Abstract
Extramammary Paget’s disease (EMPD) is an adenocarcinoma that develops mainly in the genital region of older adults. The prognosis for advanced EMPD is almost always poor; thus, novel therapeutic strategies need to be developed. HER2-targeted antibody–drug conjugates (ADCs) such as trastuzumab emtansine and [...] Read more.
Extramammary Paget’s disease (EMPD) is an adenocarcinoma that develops mainly in the genital region of older adults. The prognosis for advanced EMPD is almost always poor; thus, novel therapeutic strategies need to be developed. HER2-targeted antibody–drug conjugates (ADCs) such as trastuzumab emtansine and trastuzumab deruxtecan have proven effective against HER2-positive breast cancers; however, no studies have addressed HER2-targeted ADCs as treatments for EMPD. We examine the efficacy of ADCs against an EMPD patient-derived xenograft (PDX) model harboring pathogenic ERBB2 mutations and investigate the expression levels of HER2 using EMPD clinical samples. Trastuzumab emtansine or trastuzumab deruxtecan was administered intravenously to tumor-bearing NOD/Scid mice. Treatment with trastuzumab emtansine or trastuzumab deruxtecan was found to significantly regress EMPD-PDX tumors in only seven days, with no recurrence observed for 10 weeks. EMPD tumors extracted 48 h after drug administration revealed the TUNEL-positive ratio to be significantly higher for the HER2-targeted ADC-treated tumors than for the control tumors. EMPD patients’ clinical samples revealed a significant correlation between HER2 positivity and invasion, suggesting that HER2 status is associated with tumor progression. Our results suggest that HER2-targeted ADCs could be novel and promising treatment options for patients with EMPD, especially in ERBB2-mutant or ERBB2-overexpressed cases. Full article
(This article belongs to the Special Issue Molecular Targeting in Cancer: Imaging and Therapy)
Show Figures

Figure 1

Review

Jump to: Research

23 pages, 2659 KiB  
Review
Molecular Targeting of the Most Functionally Complex Gene in Precision Oncology: p53
by Douglas W. Brown, Perrin H. Beatty and John D. Lewis
Cancers 2022, 14(21), 5176; https://0-doi-org.brum.beds.ac.uk/10.3390/cancers14215176 - 22 Oct 2022
Cited by 4 | Viewed by 1610
Abstract
While chemotherapy is a key treatment strategy for many solid tumors, it is rarely curative, and most tumor cells eventually become resistant. Because of this, there is an unmet need to develop systemic treatments that capitalize on the unique mutational landscape of each [...] Read more.
While chemotherapy is a key treatment strategy for many solid tumors, it is rarely curative, and most tumor cells eventually become resistant. Because of this, there is an unmet need to develop systemic treatments that capitalize on the unique mutational landscape of each patient’s tumor. The most frequently mutated protein in cancer, p53, has a role in nearly all cancer subtypes and tumorigenesis stages and therefore is one of the most promising molecular targets for cancer treatment. Unfortunately, drugs targeting p53 have seen little clinical success despite promising preclinical data. Most of these drug compounds target specific aspects of p53 inactivation, such as through inhibiting negative regulation by the mouse double minute (MDM) family of proteins. These treatment strategies fail to address cancer cells’ adaptation mechanisms and ignore the impact that p53 loss has on the entire p53 network. However, recent gene therapy successes show that targeting the p53 network and cellular dysfunction caused by p53 inactivation is now possible and may soon translate into successful clinical responses. In this review, we discuss p53 signaling complexities in cancer that have hindered the development and use of p53-targeted drugs. We also describe several current therapeutics reporting promising preclinical and clinical results. Full article
(This article belongs to the Special Issue Molecular Targeting in Cancer: Imaging and Therapy)
Show Figures

Figure 1

20 pages, 1950 KiB  
Review
Peptide Receptor Radionuclide Therapy with [177Lu]Lu-DOTA-TATE in Patients with Advanced GEP NENS: Present and Future Directions
by Maria I. del Olmo-García, Stefan Prado-Wohlwend, Pilar Bello, Angel Segura and Juan F. Merino-Torres
Cancers 2022, 14(3), 584; https://0-doi-org.brum.beds.ac.uk/10.3390/cancers14030584 - 24 Jan 2022
Cited by 13 | Viewed by 4087
Abstract
This review article summarizes findings published in the last years on peptide receptor radionuclide therapy in GEP NENs, as well as potential future developments and directions. Unanswered questions remain, such as the following: Which is the correct dose and individual dosimetry? Which is [...] Read more.
This review article summarizes findings published in the last years on peptide receptor radionuclide therapy in GEP NENs, as well as potential future developments and directions. Unanswered questions remain, such as the following: Which is the correct dose and individual dosimetry? Which is the place for salvage PRRT-Lu? Whicht is the role of PRRT-Lu in the pediatric population? Which is the optimal sequencing of PRRT-Lu in advanced GEP NETs? Which is the place of PRRT-Lu in G3 NENs? These, and future developments such as inclusion new radiopharmaceuticals and combination therapy with different agents, such as radiosensitizers, will be discussed. Full article
(This article belongs to the Special Issue Molecular Targeting in Cancer: Imaging and Therapy)
Show Figures

Figure 1

Back to TopTop